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Abstract: BACKGROUND: DNA-crosslinking agents like cisplatin and mitomycin C (MMC) are indis-
pensible for the treatment of many solid malignancies. These anticancer drugs generate DNA interstrand
crosslinks (ICLs) that cause cell death by blocking replication forks. Many factors counteracting ICL-
induced DNA replication stress, including the Fanconi anemia (FA) pathway, are regulated by ubiq-
uitination and, therefore, ubiquitin ligases are potential targets for the sensitization of cancer cells to
crosslinking agents. In this study, we investigated the function of the CRL4 ubiquitin ligase in modu-
lating the response of cancer cells to ICL induction. METHODS: The two cullin paralogs CUL4A and
CUL4B, which form the CRL4 ligase scaffold, were depleted in cancer cells by small interfering RNA
followed by analysis of the cellular and biochemical responses to ICLs elicited upon cisplatin or MMC
treatment. RESULTS: We report that the combined depletion of CUL4A and CUL4B weakens an FA
pathway-dependent S phase checkpoint response. CRL4 positively stimulates the monoubiquitination of
FANCD2 required for the recruitment of XPF-ERCC1, a structure-specific endonuclease that, in turn,
contributes to the display of single-stranded DNA (ssDNA) at ICLs. After CRL4 down regulation, the
missing ssDNA results in reduced recruitment of RPA, thereby dampening activation of ATR and CHK1
checkpoint kinases and allowing for S phase progression despite ICL induction. CONCLUSION: Our
findings indicate that CRL4 promotes cell survival by potentiating an FA pathway-dependent ssDNA-
RPA signaling platform installed at ICLs. The anticancer efficacy of crosslinking agents may, therefore,
be enhanced by down regulating CRL4 activity.
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Abstract
Background: DNA-crosslinking agents like cisplatin and mitomycin C (MMC) are indispensible for the treatment of
many solid malignancies. These anticancer drugs generate DNA interstrand crosslinks (ICLs) that cause cell death by
blocking replication forks. Many factors counteracting ICL-induced DNA replication stress, including the Fanconi
anemia (FA) pathway, are regulated by ubiquitination and, therefore, ubiquitin ligases are potential targets for the
sensitization of cancer cells to crosslinking agents. In this study, we investigated the function of the CRL4 ubiquitin
ligase in modulating the response of cancer cells to ICL induction.
Methods: The two cullin paralogs CUL4A and CUL4B, which form the CRL4 ligase scaffold, were depleted in cancer
cells by small interfering RNA followed by analysis of the cellular and biochemical responses to ICLs elicited upon
cisplatin or MMC treatment.
Results: We report that the combined depletion of CUL4A and CUL4B weakens an FA pathway-dependent S phase
checkpoint response. CRL4 positively stimulates the monoubiquitination of FANCD2 required for the recruitment of
XPF-ERCC1, a structure-specific endonuclease that, in turn, contributes to the display of single-stranded DNA
(ssDNA) at ICLs. After CRL4 down regulation, the missing ssDNA results in reduced recruitment of RPA, thereby
dampening activation of ATR and CHK1 checkpoint kinases and allowing for S phase progression despite ICL induction.
Conclusion: Our findings indicate that CRL4 promotes cell survival by potentiating an FA pathway-dependent ssDNA-
RPA signaling platform installed at ICLs. The anticancer efficacy of crosslinking agents may, therefore, be enhanced by
down regulating CRL4 activity.
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Background
Platinum- and mitomycin-based drugs are used against
solid malignancies including lung, bladder, esophageal,
testicular, ovarian and cervical cancer [1]. The mechan-
ism of action of cis-diamminedichloroplatinum (II) (cis-
platin) and mitomycin C (MMC) involves the formation
of DNA interstrand crosslinks (ICLs), which lead to cell
death primarily by interfering with DNA replication [2].
A common cause of treatment failure is the emergence
of resistance developing in most patients even after an
initially favorable response. Cancer cells avoid ICL-
induced cytotoxicity by eliciting the DNA damage
response (DDR), which coordinates cell cycle progres-
sion with DNA repair [3, 4]. A universal DDR trigger is
DNA replication stress involving persistent stretches of
single-stranded DNA (ssDNA) at stalled replication
forks. The locally arising ssDNA is rapidly coated by
replication protein A (RPA), thus forming ssDNA-RPA
complexes that provide a platform for engagement of
the ataxia telangiectasia-mutated and Rad3-related (ATR)
kinase. This serine/threonine kinase phosphorylates RPA,
as well as signaling intermediates like checkpoint kinase 1
(CHK1) and histone H2AX, to trigger cell cycle check-
points [5, 6]. The efficiency of checkpoint activation deter-
mines how cancer cells respond to chemotherapy [7, 8]
and, accordingly, RPA hyperphosphorylation has been
linked to increased cisplatin resistance [9].
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The DDR cascade is driven by posttranslational modifi-
cations involving, besides phosphorylation, polypeptide
modifiers like ubiquitin [10, 11]. Cullin-RING ubiquitin li-
gases (CRLs) contain a cullin scaffold (CUL1 to 5, CUL7
or CUL9) that recruits substrate receptors to target pro-
teins for ubiquitination [12–15]. CRL activation may
require modification of cullin subunits by the ubiquitin-
like modifier NEDD8 [16]. MLN4924 (pevonedistat) is a
small-molecule antagonist of this neddylation reaction,
thereby inhibiting CRLs and preventing the ubiquitination
and subsequent degradation of proteins [17]. A prominent
target of CRL-mediated degradation under replication
stress is the replication-licensing factor CDT1, whose
function is to initiate replication forks. Normally, only one
round of DNA synthesis is allowed during each cell cycle
[14, 18]. However, by preventing the ubiquitination and
proteasomal degradation of CDT1, MLN4924 induces the
superfluous initiation of extra replication forks, causing
aberrant DNA re-replication [15, 19, 20].
Previous reports demonstrated that MLN4924 also
sensitizes cancer cells to the cytotoxic action of cisplatin
and MMC [21–23], implying that CRL inhibitors may
mitigate resistance against crosslinking agents. However,
the mechanism of this synergy between MLN4924 and
crosslinking drugs remained unclear. It was not known
which of the many possible CRLs susceptible to inhibition
by MLN4924 are implicated in the response to DNA-
crosslinking agents and, in particular, it was not known
how CRLs affect the detection or signaling of DNA damage
inflicted by these drugs. Here, we identified CRL4 as an
additional player modulating the cellular sensitivity to
cisplatin and MMC, and found that the cullin paralogs
CUL4A and CUL4B display redundant functions in regu-
lating cell survival after treatment with crosslinking agents.
The concomitant down regulation of these exchangeable
CUL4 scaffolds diminishes the Fanconi anemia (FA)
pathway-dependent recruitment of XPF-ERCC1, which as
part of a nuclease complex contributing to the formation
of ssDNA at ICL sites. Accordingly, this CRL4 depletion
interferes with the assembly of ssDNA-RPA intermediates
upon cisplatin or MMC treatment, such that activation of
ATR and the phosphorylation of RPA, CHK1 and H2AX
are reduced. Our results indicate that CRL4 activity pro-
tects from cancer cell death after treatment with crosslink-
ing agents by stimulating an FA pathway-induced S phase
checkpoint.
Methods
Cell lines and treatment
HeLa (catalog designation CCL-2) and SKOV3 cells
(catalog designation HTB-77) were purchased from
ATCC and cultured in low-glucose Dulbecco’s modified
Eagle medium (DMEM) and Roswell Park Memorial
Institute (RPMI) 1640 medium, respectivel. Cell culture
media (obtained from Gibco) were supplemented with
10% (v/v) fetal calf serum and 100 U/ml penicillin-
streptomycin. All cells were recently tested negative for
mycoplasma contamination and authenticated by short
tandem repeat profiling (Microsynth). Cells were incubated
at 37 °C in a humidified atmosphere under 5% CO2. The
cisplatin (Sigma) solutions were prepared freshly each time
in DMEM. MMC (Sigma) was dissolved as a 1.5-mM stock
solution in phosphate-buffered saline (PBS) and MLN4924
(ApexBio) as a 50-mM stock solution in dimethyl sulfoxide
(DMSO) and further diluted in cell culture medium. Cells
were treated with crosslinking agents 3 days after siRNA
transfections, except for the viability assays where the
drugs were applied 2 days after transfections.
siRNA transfections
Transfections were performed with Lipofectamine RNAi-
MAX (Invitrogen) according to the manufacturer’s proto-
col. All siRNA sequences are shown in the Additional file 1:
Table S1. The siRNA concentrations were 24 nM except
for siDDB1, which was used at a concentration of 8 nM.
Cell viability
Resazurin was purchased from Alfa Aesar and viability
measured according to the manufacturer’s instruction.
Briefly, 2000 cells per well were seeded into a 96-well
plate and 24 h later treated with the indicated drug con-
centrations. Following 2 days, resazurin was added to the
cells and fluorescence measured after 3 h (LS55 lumines-
cence Spectrometer; Perking Elmer). Cell viability was
expressed as the percentage of controls obtained in the
absence of cisplatin and IC50 values were calculated using
GraphPad Prism.
Cytotoxicity
Cell death was measured using the LDH Cytotoxicity
Assay Kit (Pierce). Briefly, 5000 cells per well were seeded
into a 96-well plate. After 24 h, cells were treated with in-
creasing concentrations of cisplatin for 2 days and the re-
leased LDH was measured in the supernatant according to
the manufacturer’s instruction. Results are calculated as
the ratio of released LDH in relation to maximal LDH ac-
tivity in each condition, and expressed as the percentage
of the ratios detected with untreated controls.
Colony formation
Cell survival was performed as described [24]. Briefly,
cells were treated with increasing concentrations of cis-
platin for 2 h, extensively washed with PBS and further
incubated in fresh media without drug for 10 days. Col-
onies were fixed and stained with 0.25% (w/v) crystal
violet solved in 80% (v/v) ethanol. Colonies composed of
at least 50 cells were counted and surviving fractions
were normalized to untreated controls.
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Immunoblotting
Cells were treated as indicated, washed once with PBS
and lysed in RIPA buffer [50 mM Tris-HCl, pH 7.5, 1%
(v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v)
SDS, 150mM NaCl, 2 mM EDTA] complemented with
1 mMN-ethylmaleimide (NEM, Sigma), 1 mM phenyl-
methylsulfonyl fluoride, PhosStop (Roche) and Complete
Protease Inhibitor cocktail (Roche) for 10 min on ice.
After sonication for 5 cycles (30 s on, 30 s off) at 4 °C (Bior-
upture Plus; Diagenode), protein concentration was deter-
mined by the BCA protein assay (Pierce) according to the
manufacturer’s instruction. Laemmli buffer was added and
boiled for 5min at 98 °C; 10 μg of protein were separated
on 4–20% Criterion TGX stain-free precast gels and trans-
ferred to nitrocellulose membranes using a Turbo transfer
device (Bio-Rad). Membranes were incubated with primary
antibodies (Additional file 1: Table S2) over night at 4 °C
followed by incubation with fluorescence-labelled second-
ary antibodies for 30min. Membranes were developed
using the Odyssey CLx Imaging System and quantification
of protein expression was performed using the Image Stu-
dio Lite Software (Li-Core Biosciences).
Cell cycle analysis
Replicative cells were labelled for 3 h with 5-ethynyl-2′-
deoxyuridine (EdU, Sigma) and fixed in 1% (w/v) para-
formaldehyde for 10 min. Coupling of Alexa Fluor 488
was performed using the Click-iT EdU Flow Cytometry
Assay Kit (Invitrogen) according to the manufacturer’s
instruction. DNA contents were quantified by 4′,6-dia-
midino-2-phenylindole (DAPI) staining. Mitotic cells
were visualized by incubation with the phospho-histone
H3 (pH 3) antibody (Additional file 1: Table S2) for 2 h,
followed by a 1-h secondary antibody incubation using
anti-mouse Alexa 647. Approximately 10,000 and 50,000
cells per sample were analyzed for EdU and pH 3, respect-
ively, using a Fortessa LSR ll flow cytometer followed by
data analysis using the FlowJo software.
Immunofluorescence microscopy
Cells were grown on glass coverslips and treated as indi-
cated 3 days after siRNA transfections. Following the indi-
cated incubation periods, cells were washed with PBS and
pre-extraction buffer [25mM HEPES, pH 7.5, 50mM
NaCl, 1 mM EDTA, 3mM MgCl2, 300mM sucrose, 0.5%
(v/v) Triton X-100] was added for 2min [25]. Cells were
fixed with 4% (w/v) paraformaldehyde in PBS for 10min,
followed by incubation with PBS containing 0.2% (v/v)
Triton X-100 and 3% (w/v) bovine serum albumin (BSA)
for 10min. Coverslips were then washed with 1% BSA in
PBS and incubated with primary antibodies (Addional
file 1, Table S2) diluted with 1% BSA in PBS. Secondary
antibodies, diluted with 1% BSA in PBS and containing
DAPI were added for 30min at 37 °C after washing three
times for 10min with 1% BSA in PBS. Images of immuno-
stained cells were taken with an SP8 confocal microscope
(Leica) and analysed with the ImageJ software.
Monitoring of ssDNA
To detect ssDNA, cells were labelled with 25 μM 5-iodo-
2′-deoxyuridine (IdU, Sigma) 30 h prior to anticancer
drug treatment as described [5]. The ssDNA was de-
tected using an anti-IdU antibody (BD Biosciences)
under native conditions. To quantify the totally incorpo-
rated IdU, DNA was denaturated with 2M HCl in 0.5%
(v/v) Tween 20 for 40 min and washed twice with 0.1M
Na-borate buffer, pH 9.0, prior to antibody staining. Im-
ages taken with an SP8 confocal microscope (Leica) were
analysed using the ImageJ software.
Quantitative reverse transcriptase-PCR (qRT-PCR)
To determine the knock down efficiency, mRNA was ex-
tracted 3 days after siRNA transfection using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s in-
structions. Thereafter, cDNA was synthesized from 500
ng mRNA with the iScript cDNA synthesis kit from Bio-
Rad. Gene specific primers were designed using the
NCBI Primer-BLAST [26] and GAPDH served as the in-
ternal control (Additional file 1: Table S1). Quantitative
PCR was performed using the KAPA SYBR Fast qPCR
Master Mix (2x) kit (KAPA Biosystems) according to the
manufacturer’s instructions. The amplification condi-
tions in the Bio-Rad CFX instrument consisted of an ini-
tial step of 3 min at 95 °C followed by 40 cycles of 3 s at
95 °C and 40 s at 60 °C. The delta-delta ct method was
used to determine relative mRNA expression levels be-
tween siRNA-transfected samples and control samples
transfected with non-coding siRNA [27].
In vitro protein dephosphorylation
HeLa cells were harvested 3 days after siRNA transfections
and lysed for 30min on ice under mild lysis conditions [1%
(wt/vol) NP-40, 0.5% (wt/vol) SDS, complete protease in-
hibitor cocktail, EDTA-free (Roche)] followed by sonic-
ation for 10 cycles (30 s on, 30 s off) at 4 °C (Biorupture
Plus, Diagenode). Cell lysates were then diluted in CIP buf-
fer (100mM NaCl, 50mM Tris-HCl, pH 8.0, 10mM
MgCl2, 1 mM DTT, complete protease inhibitor cocktail -
EDTA-free) and complemented with calf intestinal alkaline
phosphatase (2 U/μg of protein, Sigma), and / or PhosStop
(Roche) and / or 1mMN-ethylmaleimide (NEM, an inhibi-
tor of deubiquitinases) [28]. Reactions were incubated for
2 h at 37 °C, boiled in Laemmli buffer for 5min and sub-
jected to Western blot analysis.
Statistical analyses
GraphPad Prism 5 was used to perform statistical ana-
lyses. The data presented were acquired from a minimum
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of two independent experiments. The Student’s t-test (un-
paired, two-tailed) was used to analyze immunoblot and
flow cytometry assays and all data are shown as the
mean ± SEM. Immunofluorescence microscopy experi-
ments were analyzed using 1-way ANOVA according to
Kruskal-Wallis. Median values were presented as horizon-
tal lines, boxes show the upper and lower quartiles and
whiskers the 10-90th percentiles. P values of *P < 0.05,
**P < 0.01 and ***P < 0.001 were considered to indicate
statistical significance.
Results
CUL4A/B depletion potentiates the cytotoxicity of
crosslinking agents
We started out with short-term viability assays, based on
the cell-mediated resazurin reduction, to establish that
the neddylation inhibitor MLN4924 potentiates the cyto-
toxic effect of the crosslinking agents cisplatin and
MMC in HeLa cells, as demonstrated before with several
other cancer cell lines [21, 22]. MLN4924 at a concen-
tration of 10 μM reduces the IC50 of cisplatin from ~ 10
to ~ 2.5 μM and the IC50 of MMC from ~ 4 to ~ 1.5 μM
(Fig. 1a). MLN4924 also increases the cytotoxicity of cis-
platin and MMC in SKOV3 ovarian carcinoma cells
(Additional file 1: Figure S1a and S1b).
Next, we depleted different cullins by siRNA transfec-
tions to understand which of the possible cullin targets
of neddylation modulates this vulnerability to DNA-
crosslinking agents. Cell viability assays, carried out in
the presence of 5 μM cisplatin, confirmed a potentiation
of cisplatin toxicity upon down regulation of CUL3 as
reported before for SKOV3 and ES2 ovarian carcinoma
cells [29]. The new finding of this screen is that a
sensitization to cisplatin cytotoxicity is also detected
upon simultaneous down regulation of the two scaffold
paralogs of CRL4, i.e., CUL4A and CUL4B (Fig. 1b).
Dose dependence experiments showed that this co-
depletion of CUL4A and CUL4B mimics to a consider-
able extent the sensitizing effect of MLN4924 when cells
are treated with cisplatin or MMC for 48 h (Fig. 1c and
d). Nearly the same increase of sensitivity to cisplatin
was achieved upon depletion of the CRL4 adaptor pro-
tein Damaged DNA-binding 1 (DDB1) instead of the
CUL4A/B scaffold. Instead, no sensitization was elicited
upon individual depletion of only one of the cullins,
CUL4A or CUL4B, indicating that the two interchange-
able scaffolds have a redundant function. These results
were confirmed using distinct combinations of siRNA
sequences targeting CUL4A and CUL4B to exclude off-
target effects (Additional file 1: Figure S1c and S1d). The
efficiency of protein down regulation upon siRNA trans-
fections is documented in Additional file 1: Figure S2.
Further assays measuring the release of lactate de-
hydrogenase as a marker of membrane disruption (Fig. 1e)
confirmed that the CUL4A/B depletion enhances cisplatin-
induced cell death. Finally, the increased cytotoxicity of
cisplatin upon a combined CUL4A/B depletion, but not
after down regulation of only one of the cullins
Fig. 1 CUL4A/B depletion potentiates ICL cytotoxicity. a HeLa cells were incubated for 48 h with cisplatin (panel on the left) or MMC (panel on
the right) together with MLN4924 as indicated (N = 5–10 experiments, error bars show s.e.m.). Cell viability is given as the percentage of controls
not exposed to cisplatin. b HeLa cells were transfected with indicated siRNA, incubated with 5 μM cisplatin and tested after 48 h. Viability is
expressed as the percentage of control values obtained in the absence of cisplatin (N = 3–5); siNC, non-coding RNA control. Asterisks indicate
significantly lower viability in depleted cells relative to non-coding controls (*P < 0.05 and **P < 0.01, unpaired two-tailed t-test). c Cells were
transfected with the indicated siRNAs, incubated with cisplatin and tested for viability after 48 h (N = 5). d Cell viability after exposure to MMC
(N = 5). e Cytotoxicity assays measuring the release of LDH from siRNA-transfected cells during 48-h treatments with cisplatin (N = 5–10). f Colony-
forming assays after exposure of siRNA-transfected cells to the indicated cisplatin concentrations. The resulting colony numbers are normalized to
non-exposed controls (N = 5)
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individually, was confirmed in a long-term colony-forming
assay (Fig. 1f).
CUL4A/B depletion reduces H2AX/RPA phosphorylation
upon ICL induction
Considering that CUL4A and CUL4B have an impact on
the cytotoxicity of crosslinking agents, we tested the role of
CRL4 in modulating DNA damage signaling following ICL
induction. Resolution of ICLs by the FA pathway generates
transient DNA breaks and ssDNA intermediates, which ac-
tivate the checkpoint kinases ATR and ATM [5, 8, 30–32].
Phosphorylation of downstream factors like histone H2AX
and the ssDNA-binding protein RPA generates docking
motifs for effectors that mediate S phase checkpoints es-
sential for DNA repair [3, 33–35]. Phosphorylation of
H2AX (generating γH2AX) as well as phosphorylation of
RPA2, the middle subunit of RPA, on serines 4/8 (generat-
ing pS4/8) and serine 33 (generating pS33), was assessed
by immunofluorescence using phospho-specific antibodies.
CRL4-proficient cells respond to cisplatin treatment with a
dose-dependent increase of γH2AX, pS4/8 and pS33, but
this phosphorylation was markedly reduced for the direct
ATR targets pS33 and γH2AX (Fig. 2a-c) in CUL4A/B-de-
pleted cells. A significant reduction was also observed in
CUL4A/B-depleted cells for the formation of pS4/8, but
only at the highly cytotoxic cisplatin concentration of
20 μM (Fig. 2d).
The phosphorylation of RPA2 at serines 4, 8 and 33
was further investigated by immunoblotting (Fig. 2e).
Some increase of RPA2 phosphorylation was observed in
CUL4A/B-deficient cells without any genotoxic treat-
ment. This response is expected from the loss of CRL4-
dependent licensing regulation (see Discussion). In blots
with the generic RPA2 antibody, there was an apparent
reduction of the overall RPA2 signal in CRL4-deficient
cells compared to the CRL4-proficient counterparts.
However, we did not find in the literature any indication
that CRL4 would positively regulate RPA stability, such
that a CRL4 down regulation could result in diminished
RPA2 levels. We favor the view that the higher back-
ground phosphorylation of RPA2 in CRL4-deficient cells
results in a reduced signal intensity in the electrophor-
etic position corresponding to the unmodified protein.
This interpretation is supported by the immunofluores-
cence analyses (with quantifications) of Fig. 3, where in
the absence of any crosslinking agent there is no reduction
of RPA2 in CRL4-deficient cells compared to controls.
When using phospho-specific antibodies, the immuno-
blots of Fig. 2e confirmed the observed reduction of pS4/8
and pS33 in CUL4A/B-depleted cells compared to CRL4-
proficient counterparts after 24-h cisplatin exposures This
finding was validated using a second siRNA sequence for
the down regulation of CUL4A and CUL4B (Additional
file 1: Figure S3a and S3b). To ensure that the observed
shift in RPA2 electrophoretic mobility results from phos-
phorylation and not from a hypothetical ubiquitination by
CRL4, cell lysates were subjected to phosphatase incuba-
tion prior to immunoblotting. Such a dephosphorylation
clearly diminished the pS33 signal, thus confirming that
we detected truly phosphorylated RPA2 (Additional file 1:
Figure S3c). These results indicate that CUL4A/B-defi-
cient cells are impaired in DNA damage signaling follow-
ing cisplatin treatment.
CRL4 deficiency impairs interstrand crosslink-dependent
assembly of ssDNA-RPA complexes
In view of the observation that the cisplatin-dependent
RPA phosphorylation is reduced in CRL4 deficient cells,
we next tested whether CRL4 is required for the recruit-
ment of RPA to sites of cisplatin damage. By immuno-
fluorescence analysis, some increase of RPA2 foci in
chromatin was observed in CUL4A/B-deficient cells
even without any genotoxic treatment (Fig. 3a and b).
This response is expected from the loss of CRL4-
dependent regulation of CDT1 described in previous re-
ports (see Discussion). The replication licensing factor
CDT1 is nearly completely degraded within 24 h after
genotoxic stress caused by cisplatin in CRL4-proficient
cells (Additional file 1: Figure S4a and S4b). Instead, the
CUL4A/B depletion results in a pronounced stabilization
of CDT1, such that the cells maintain high CDT1 levels
despite cisplatin exposure. This results in uncoupling of
the minichromosome maintenance (MCM) helicase ac-
tivity and an uncontrolled re-replication that triggers
RPA recruitment and other ATR-dependent signaling
reactions [36]. However, this RPA recruitment to chroma-
tin was not or only slightly further increased by cisplatin
treatment of CRL4-deficient cells. As a consequence,
CUL4A/B-depleted cells exposed to cisplatin display sig-
nificantly lower levels of RPA foci when compared to
CRL4-proficient controls treated with the same cisplatin
concentrations (Fig. 3a and b).
Next, we tested whether RPA recruitment to chroma-
tin in response to cisplatin damage is related to the
ssDNA formation. For that purpose, ssDNA induction
was assessed using a well-established method based on
the incorporation of 5-iodo-2′-deoxyuridine (IdU), which
allows for the probing of cells with an antibody that binds
to IdU only in the ssDNA conformation. Using this same
approach, Huang et al. [5] did not detect ssDNA interme-
diates after 4- to 6-h treatments with MMC or psoralen
(plus UV-A radiation). In agreement with this earlier re-
port, we also observed that ssDNA as well as pS33 remain
below the detection threshold within the first 6 h of cis-
platin exposure (Additional file 1: Figure S4c-e). However,
a longer incubation time of 24 h revealed the formation of
clearly detectable ssDNA foci in control cells (Fig. 3a).
Again, an increase of ssDNA was observed in CUL4A/B-
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deficient cells even without genotoxic treatment, as
expected from the loss of CRL4-dependent licensing regu-
lation and the notion that the display of ssDNA provides
an initial signal for ATR-mediated S phase checkpoint acti-
vation upon uncontrolled re-replication [36]. Consistent
with the differential recruitment of RPA, ssDNA foci were
substantially reduced in CUL4A/B-depleted cells compared
to CRL4-proficient controls exposed to the same cisplatin
concentrations (Fig. 3a and c). It is important to ascertain
in these experiments that IdU is equally incorporated into
DNA under the different experimental conditions, as
shown by immunofluorescence after DNA denaturation
(Additional file 1: Figure S4f-g).
To demonstrate the general relevance of the above-
described findings, we also assessed the appearance of
ssDNA and consequent RPA phosphorylation in MMC-
exposed HeLa and SKOV3 cells (Fig. 3d and e). Immuno-
fluorescence quantifications confirmed that the CUL4A/B
depletion counteracts partially the ICL-dependent display
of ssDNA and pS33 upon exposure to the crosslinking
agent (Fig. 3f and g). Decreased pS33 and pS4/8 levels
upon CUL4A/B depletion were also found in immuno-
blots following MMC treatment of both HeLa and SKOV3
cells (Additional file 1: Figure S4 h). These results indicate
that CRL4 activity is required for the generation of a
ssDNA-RPA signaling platform essential for the DDR
mitigating the cytotoxicity of crosslinking agents.
FANCD2-dependent ssDNA formation upon cisplatin
treatment
The FA pathway is responsible for the recruitment of
nucleases required for the unhooking of crosslinked
bases, thus inducing double strand breaks and ssDNA
intermediates at ICL sites [37–42]. To corroborate the
role of CRL4 in stimulating the formation of ssDNA-
RPA complexes in cisplatin-treated cells, we exploited
the increased level of ssDNA foci induced by 5-μM
cisplatin incubation for 24 h (Fig. 4a and b). After this
incubation treatment for 24 h, 95 ± 4.3% (N = 7) of con-
trol cells remain viable, arguing against the possibility
that the accumulation of ssDNA is due to replication ca-
tastrophe caused by severely damaged DNA. We then
depleted, by siRNA transfection, different members of
the FA pathway that have been implicated in DNA dam-
age processing and RPA recruitment. Immunofluores-
cence analyses (Fig. 4a) and subsequent quantifications
(Fig. 4b) revealed that a depletion of FANCD2 is suffi-
cient to prevent ssDNA formation detected after 24 h of
cisplatin treatment. This observation, although unex-
pected in view of previous findings focusing on 4–6 h as
the time points for analyses [5], is in line with the notion
that FANCD2 constitutes a central member of the FA
pathway that organizes downstream effector nucleases
[37–40]. This dependence on FANCD2 indicates that
ssDNA formation is triggered by ICLs rather than other
forms of damage resulting from cisplatin. We also used
the siRNA-mediated strategy to down regulate the up-
stream FA pathway members FANCM and FAAP24 [43,
44] as well as the core nucleotide excision repair subunit
XPA. Unlike FANCD2, depletion of these factors failed
to detectably reduce ssDNA formation during the same
5-μM cisplatin treatment for 24 h (Fig. 4a and b). It is
possible, however, that low residual level of these factors
remaining after siRNA transfections (see Additional file
1: Figure S2 for the efficiency of the siRNA-mediated de-
pletion) were sufficient for their action in the display of
ssDNA after ICL induction.
Additionally, RPA2 phosphorylation on serine 33 was
assessed (Fig. 4a and c) to prove that depletion of
FANCD2 not only suppresses the formation of ssDNA
but also the consequent foci of phosphorylated RPA2 in
cisplatin-exposed cells. This result was confirmed by im-
munoblots using two distinct siRNA sequences to deplete
FANCD2 (Additional file 1: Figure S5a and S5b). In all
cases, the lack of FANCD2 reduced markedly the level of
pS33 in cisplatin-treated cells. We concluded that the ex-
perimental conditions of our study verify the involvement
of FANCD2 in the induction of ssDNA serving as a hub
for the initiation of RPA signaling at ICL sites.
CUL4A/B depletion impedes recruitment of FANCD2 and
XPF-ERCC1
The above results prompted us to use FANCD2 as the
molecular target to test whether CRL4 might impact on
(See figure on previous page.)
Fig. 2 CRL4 depletion reduces H2AX and RPA phosphorylation upon cisplatin exposure. a HeLa cells were transfected with siRNA and subjected
to 24-h cisplatin treatments as indicated. For the detection of γH2AX, pS33 and pS4/S8 (RPA2 phosphorylated at serine 33 and 4/8, respectively),
fixed cells were stained with phospho-specific antibodies. DAPI visualizes the nuclei. b Quantification of nuclear fluorescence representing pS33
induced by the indicated treatments (N = 210–580 nuclei from 2 to 4 experiments). c Quantification of γH2AX (N = 510–590 nuclei from 3 to 4
experiments). d Quantification of pS4/8 foci (N = 180–250 nuclei from 2 experiments). In panels b, c and d, horizontal lines represent median
values, boxes 25-75th percentiles and whiskers 10-90th percentiles. ***P < 0.001 (1-way ANOVA according to Kruskal-Wallis). Scale bar: 10 μm. e
HeLa cells were transfected with siCUL4A/B, or with siNC, incubated with 5 μM cisplatin and analyzed following the indicated periods. Whole cell
lysates were probed with antibodies against RPA2, pS33 and pS4/8. Tubulin served as the loading control. The graphs represent quantifications of
pS33 and pS4/8, normalized to tubulin, from 3 to 5 experiments. All values are shown relative to the respective phospho-protein observed in
siNC-transfected cells after a 24-cisplatin treatment. Asterisks indicate significant difference between CUL4A/B-depleted cells and non-coding
controls (*P < 0.05, **P < 0.01; unpaired, two-tailed t-test)
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Fig. 3 (See legend on next page.)
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the FA pathway in cisplatin-damaged cells. A central
step in repair of ICLs is monoubiquitiation of FANCD2
by the FA core machinery. Subsequently, a nuclease
complex that includes the structure-specific endonucle-
ase XPF-ERCC1 is recruited to chromatin in order to
unhook the ICLs [30, 38, 45]. As expected, exposure to
cisplatin increases the nuclear foci of FANCD2 and
ERCC1, and, interestingly, this recruitment is stimulated
by CRL4 activity. The down regulation of CUL4A/B re-
duces the level of FANCD2 foci (Fig. 5a and b) as well
as the level of ERCC1 foci in cisplatin-treated cells (Fig.
5c and d). These findings imply that XPF-ERCC1 may
play a key role in the formation of ssDNA at ICLs. This
view is supported by the observation that down regula-
tion of ERCC1 with two different siRNA sequences re-
duces both the ssDNA foci and the consequent RPA
phosphorylation in cisplatin-treated cells (Additional file
1: Figure S5c-e).
As stated above, monoubiquitination of FANCD2 is a
key prerequisite for recruitment of the downstream nu-
clease complex including XPF-ERCC1 to ICL sites [37].
We therefore tested whether CRL4 might influence the
FANCD2 ubiquitination in response to crosslinking
agents. Upon analysis in immunoblots, the monoubiqui-
tination of FANCD2 is indeed impaired in CUL4A/B-de-
pleted cells relative to CRL4-proficient controls (Fig. 5e).
Quantifications are presented in Fig. 5f as the ratio of
ubiquitinated and unmodified FANCD2 for each condi-
tion over three independent experiments. After treatment
with 5-μM cisplatin, ~ 50% of FANCD2 is ubiquitinated in
control cells. Instead, in CUL4A/B-depleted cells, only ~
30% of FANCD2 molecules appear in this modified form
after the same cisplatin exposure. These results indicate
that CRL4 activity stimulates the monoubiquitination of
FANCD2 and, accordingly, the FANCD2-dependent
recruitment of downstream nucleases.
CUL4A/B depletion suppresses the S phase checkpoint
after exposure to crosslinking agents
Upon DNA damage, replication is inhibited by S phase
checkpoints to ensure repair of the damage before cells
enter mitosis, which is an important strategy to prevent
cell death by replication catastrophe. As the above
described results indicate that CRL4 supports damage sig-
naling by stimulating the FANCD2-ERCC1-dependent
formation of the ssDNA-RPA complexes, we next assessed
whether the abrogated signaling in CRL4-deficient cells af-
fects S-phase progression. HeLa cells depleted of CUL4A/
B were incubated for 24 h with cisplatin or MMC. There-
after, DNA content and DNA synthesis were monitored
by measuring 4′,6-diamidino-2-phenylindole (DAPI) bind-
ing and 5-ethynyl-2′-deoxyuridine (EdU) incorporation,
respectively, in flow cytometry analyses. When cells were
transfected with non-coding control RNA, cisplatin inhib-
ited their replicative DNA synthesis in a dose-dependent
manner (Fig. 6a and b). At a cisplatin concentration of
5 μM, the EdU incorporation was decreased by nearly
90%. As expected [20], the CUL4A/B depletion on its own
was sufficient to elicit intra-S phase checkpoint responses
lowering the rate of DNA synthesis. However, such a re-
duced DNA synthesis compared to non-coding siRNA
controls was observed only as long as the cells were not
exposed to cisplatin. This is demonstrated by the fact that
the combination of CUL4A/B depletion and 5-μM
cisplatin treatment resulted in a 2-fold higher EdU incorp-
oration compared to the same cisplatin treatment in
CRL4-proficient controls (Fig. 6b).
This elevated DNA synthesis is in agreement with the
dampened activation of the intra-S checkpoint transducer
CHK1, a direct target of ATR. An increase of CHK1 phos-
phorylation (generating pCHK1) was observed in CRL4-
proficient HeLa cells treated with cisplatin lasting at least
24 h after initiation of drug exposure (Fig. 6c and d). Al-
though there was an initial increase of pCHK1 in CRL4-
deficient cells, at later timepoints pCHK1 levels were
significantly lower. In MMC-exposed cells, CUL4A/B
depletion also impedes CHK1 phosphorylation, albeit par-
tially (Additional file 1: Figure S6a). Although CHK1 had
been identified as a possible CRL4 substrate [46], we did
not observe any overall changes of CHK1 protein level.
One may argue that the reduced phosphorylation of CHK1
in CUL4A/B-depleted cells exposed to crosslinking agents
results from a compromised viability. However, over three
independent experiments the combined CUL4A/B defi-
ciency had no statistically significant influence on the phos-
phorylation of CHK2 protein in cisplatin-treated cells
(See figure on previous page.)
Fig. 3 CRL4 deficiency impairs the interstrand crosslinks dependent assembling of ssDNA-RPA complexes. a HeLa cells were transfected with the
indicated siRNA and labeled with IdU prior to cisplatin exposure for 24 h. After fixation, cells were stained for RPA2 and ssDNA. DAPI was used to
visualize the nuclei. b Quantification of nuclear fluorescence representing RPA2 foci (N = 360–680 nuclei from 3 to 6 experiments). c
Quantification of nuclear fluorescence representing ssDNA induced by the indicated treatments (N = 230–530 nuclei from 3 to 4 experiments). d
HeLa cells were transfected with siRNA and labeled with IdU prior to MMC exposure for 24 h. For the detection of pS33 (RPA2 phosphorylated at
Ser33), fixed cells were stained with phospho-specific antibodies. DAPI was used to visualize the nuclei. e SKOV3 cells were transfected with siRNA
as indicated, treated for 24 h with MMC, and stained for pS33 and ssDNA. f Quantification of nuclear fluorescence representing ssDNA and pS33
foci in HeLa cells (N = 262–349 nuclei from 2 experiments). g Quantification of ssDNA and pS33 foci in SKOV3 cells (N = 200–240 nuclei from 2
experiments). In panels b, c, f, g, horizontal lines represent median values, boxes 25-75th percentiles and whiskers 10-90th percentiles. *P < 0.05,
***P < 0.001 (1-way ANOVA according to Kruskal-Wallis). Scale bar: 10 μm
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(Additional file 1: Figure S6b and S6c). These findings indi-
cate that CRL4 activity stimulates mainly the ATR/CHK1
signaling pathway in cells treated with crosslinking agents.
An identical response with stimulation of DNA synthesis
in CRL4-deficient relative to CRL4-proficient counterparts
was detected after exposure to MMC (Additional file 1:
Figure S6d and S6e). These findings confirm that the cells
respond to cisplatin and MMC treatment with an effective
S phase checkpoint that suppresses DNA synthesis. How-
ever, this cell cycle checkpoint is at least in part abrogated
by concomitant depletion of the CRL4 scaffold proteins
CUL4A and CUL4B, such that cisplatin- or MMC-exposed
Fig. 4 FANCD2-dependent ssDNA formation upon cisplatin treatment. a HeLa cells were transfected with siRNA and labeled with IdU prior to
cisplatin exposure for 24 h. After fixation, cells were stained for ssDNA, using an anti-IdU antibody, and for pS33 (RPA2 phosphorylated at Ser33).
DAPI was employed to visualize the nuclei. b Quantification of nuclear fluorescence representing ssDNA induced by the indicated treatments
(N = 368–594 nuclei from 3 experiments). c Quantification of nuclear fluorescence representing RPA2 phosphorylation at Ser33 (N = 440–580
nuclei from 2 to 3 experiments). In panels b and c, horizontal lines represent median values, boxes 25-75th percentiles and whiskers 10-90th
percentiles. *P < 0.05, **P < 0.01, ***P < 0.001 (1-way ANOVA according to Kruskal-Wallis). Scale bar: 10 μm
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and CUL4A/B-depleted cells display higher rates of DNA
synthesis than control cells treated with these same cross-
linking drug. Cell cycle analyses established that a deple-
tion of FANCD2 or ERCC1 results in a defective S phase
checkpoint and elevated DNA synthesis in cisplatin-treated
cells (Additional file 1: Figure S6f and S6 g) exactly as ob-
served after CUL4A/B depletion (Fig. 6a). This identical
checkpoint defect is consistent with the notion that CRL4
activity positively regulates the observed ICL –> FANCD2
–> XPF-ERCC1 –> ssDNA-RPA –> ATR/CHK1 pathway.
We next tested whether the weakened S phase check-
point, translating to an accelerated S phase progression,
leads to an increase of the M phase population. For that
purpose, cisplatin-treated cells were stained for DNA con-
tent and histone H3 phosphorylation at position Ser10
(pH3), a well-established marker of mitosis, and subse-
quently analyzed by flow cytometry (Fig. 6e). The propor-
tion of cells reaching M phase was reduced upon cisplatin
exposure in a dose-dependent manner. However, the
CUL4A/B depletion doubled the fraction of M phase cells
relative to the non-coding siRNA controls (Fig. 6f). Be-
cause the tested cisplatin concentration of 5 μM is toxic in
CUL4A/B-depleted cells, we concluded that the CUL4A/B
deficiency allows for entering mitosis despite irreparable
DNA damage, thereby causing mitotic catastrophe.
Inhibition of Neddylation recapitulates the effects of
CUL4A/B depletion
Our results suggest that the cytotoxic effect of the ned-
dylation inhibitor MLN4924 is mediated partially by
Fig. 5 CRL4 depletion impairs recruitment of FANCD2 and XPF-ERCC1. a HeLa cells were transfected with siRNA and labeled with IdU prior to 24-
h cisplatin exposures. After fixation, cells were stained for FANCD2 and ssDNA (using an anti-IdU antibody). DAPI was used to visualize the nuclei.
b Quantification of nuclear fluorescence representing FANCD2 foci induced as indicated (N = 590–700 nuclei from 3 experiments). c Cells were
transfected with siRNA and labeled with IdU prior to 24-h cisplatin exposures. After fixation, cells were stained for ERCC1 and ssDNA. DAPI was
used to visualize the nuclei. d Quantification of nuclear fluorescence representing ERCC1 foci (N = 350–480 nuclei from 3 experiments). e
Immunoblot showing the monoubiquitination of FANCD2 after 24-h cisplatin exposures. Upper bands represent monoubiquitinated FANCD2.
Tubulin was used as the loading control. f Ratio of monoubiquitinated FANCD2 (FANCD2-Ub) and unmodified FANCD2 (N = 3). In panels b and d,
horizontal lines represent median values, boxes the 25-75th percentiles and whiskers the 10-90th percentiles. ***P < 0.001 (1-way ANOVA
according to Kruskal-Wallis). In panel f, data are presented as mean ± SEM. *P ≤ 0.05 (unpaired, two-tailed t-test). Scale bar: 10 μm
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inactivation of the CRL4 ligase (Fig. 1). For further con-
firmation, we examined whether MLN4924 would reiter-
ate the effect of CUL4A/B depletion on the S-phase
checkpoint regulation following cisplatin and MMC ex-
posure (Fig. 7). Efficient CRL4 inhibition is indicated by
the disappearance of the slower migrating CUL4 bands,
representing the active neddylated form, upon incuba-
tion of HeLa cells with MLN4924. The inhibitor alone
only weakly activates the DNA damage response,
reflected by slight increases in pS33, pS4/8 and pCHK1,
whereas cisplatin and MMC induce a pronounced phos-
phorylation of RPA2 and CHK1, accompanied by nearly
complete degradation of CDT1. This ICL-induced DNA
damage response was progressively suppressed in the
presence of increasing MLN4924 concentrations, thus
supporting the described role of CRL4 in stimulating FA
pathway-induced ssDNA signaling.
Discussion
This study was instigated by the surprising observation
that, in the presence of the DNA-crosslinking agents cis-
platin and MMC, a CRL4 deficiency causes the same cell
cycle checkpoint defect as a depletion of FANCD2 or
ERCC1. Therefore, our findings indicate that CRL4
positively regulates a FANCD2- and ERCC1-dependent
checkpoint response that depends on the local deploy-
ment of ssDNA. This involvement of the FA pathway,
which is dedicated to the repair of ICLs [8, 31, 32], im-
plies that the ICL lesions induced by cisplatin and MMC
constitute the actual trigger for the observed ssDNA in-
duction. Cisplatin, MMC and other crosslinking agents
are highly cytotoxic because the resulting ICLs interfere
with processes requiring separation of the two DNA
strands and thereby block DNA replication [1]. Although
it is well known that the repair of ICLs during DNA rep-
lication requires the FA pathway, the mechanism by
which crosslinking agents induce the S phase checkpoint
is less well understood. A previous study, describing the
role of the FA pathway after 4- to 6-h treatments with
MMC or psoralen (plus ultraviolet irradiation), did not
detect any ssDNA intermediates. The authors of that
earlier study reported that, during this time window of
4–6 h, the FA pathway members FANCM and FAAP24
are able to initiate an RPA-dependent checkpoint re-
sponse to ICLs without generating ssDNA intermediates
[5]. In agreement with this earlier report, we also ob-
served that ssDNA levels remain below the detection
threshold within 6 h of cisplatin or MMC exposure.
Fig. 6 Suppression of the S phase checkpoint upon CRL4 depletion. a HeLa cells were siRNA-transfected and incubated for 24 h with cisplatin.
The resulting cell cycle distribution was analyzed by flow cytometry. Rectangles contain S phase cells. b Quantification of EdU incorporation in S
phase cells after the indicated treatments. EdU intensities are normalized to siNC controls not exposed to cisplatin (N = 5). c Immunoblot showing
pCHK1 (phosphorylated at Ser345) after exposure to 20 μM cisplatin. d Quantification of pCHK1 normalized to GAPDH. Values are expressed
relative to the amount of pCHK1 in CRL4-proficient cells treated for 24 h with cisplatin (N = 3–5). e CUL4A/B-depleted cells were incubated for 24
h with cisplatin as indicated. Mitotic cells were stained with antibodies against pH3 and DAPI, and analyzed by flow cytometry. Rectangles
indicate pH3-positive cells. f Percentage of mitotic cells resulting from the indicated treatments (N = 3–5). In panels b, d, f, data are presented as
mean ± SEM. *P≤ 0.05, **P < 0.01 (unpaired, two-tailed t-test)
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However, abundant ssDNA foci, which depend on
FANCD2 for the recruitment of a nuclease complex
comprising ERCC1, are detected after 24-h treatments
with these same crosslinking agents. The ssDNA foci
emerging in a time-dependent manner ultimately reinforce
an S phase checkpoint by recruitment of RPA and subse-
quent engagement and activation of the ATR and CHK1
protein kinases. We conclude that, in addition to the previ-
ously discovered ssDNA-independent and short-term
checkpoint response to ICLs, there is a ssDNA-dependent
and sustained response to the same lesions, together cul-
minating in cell cycle arrest. We unexpectedly observed
that cells lacking CLR4 activity are impaired in this
ssDNA-dependent signaling response to ICLs and the
functional consequence of our finding is that a CLR4 defi-
ciency potentiates the cytotoxicity of cisplatin and MMC.
Our report establishes an unforeseen functional link
between two distinct ubiquitination systems, i.e., the FA
pathway and CRL4 complexes. CRL4 ubiquitin ligases
are formed by assembly of one of two closely related
scaffold proteins (CUL4A or CUL4B) with the adaptor
protein DDB1, which associates with substrate receptors.
The scaffold subunit also binds to the RING finger protein
RBX1 mediating the association with ubiquitin-delivering
enzymes. The two paralogs CUL4A and CUL4B share
high sequence similarity. Importantly, these CUL4A/B
paralogs are amplified or overexpressed in human carcin-
omas and provide negative prognostic markers for survival
[47]. CRL4 complexes employ a variety of substrate recep-
tors that target specific proteins for ubiquitination [12,
13]. For example, the CRL4CDT2 ubiquitin ligase promotes
degradation of the replication licensing factor CDT1 after
replication origin firing to ensure that DNA is replicated
only once per cell cycle [18, 48]. Exposure to DNA-
damaging agents also induces rapid CDT1 proteolysis
through CRL4-mediated ubiquitination [49, 50], whereas
ectopic CDT1 expression promotes DNA re-replication
[18, 20]. Accordingly, CRL4-deficient cells display higher
constitutive levels of CDT1 and the resulting deleterious
re-replication has been shown to activate DDR signaling
[20, 35, 36]. A cursory interpretation of our findings
might, therefore, implicate the aberrant stabilization of cell
cycle factors like CDT1 and p21, as described to explain
the efficacy of pevonedistat against melanoma cells [51],
together with deregulated MCM activity [36], as the cause
of an increased sensitivity of CRL4-deficient cells to cross-
linking agents. However, the lack of CRL4 increases
ssDNA levels only in undamaged cells and this slightly
higher ssDNA content, seen in comparison to CRL4-
proficient counterparts, is not further enhanced by expos-
ure to cisplatin or MMC. On the contrary, in the presence
of such crosslinking agents the extent of ssDNA remains
significantly lower in CRL4-deficient cells compared to
the CRL4-proficient controls. This observation points to
an additional, fundamentally different effect of CRL4
down regulation that suppresses the ICL-induced ssDNA
formation, thus limiting ssDNA-RPA signaling and the
consequent activation of checkpoint kinases. Conse-
quently, the ICL-triggered phosphorylation of RPA2 (at
position Ser33) and the phosphorylation of downstream
Fig. 7 MLN4924 recapitulates the effects of CUL4A/B depletion. HeLa cells were treated simultaneously with an ICL-inducing agent and MLN4924
as indicated. The cisplatin and MMC concentrations were 5 μM and 1 μM, respectively. After 24 h, cells were analyzed to determine CUL4A/B
modifications, RPA2, CDT1 and CHK1, and the phosphorylation of RPA2 (pS4/8 and pS33) and CHK1 (pCHK1). Tubulin served as the
loading control
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effectors like H2AX is reduced in cells lacking CRL4 activ-
ity compared to CRL4-proficient controls.
A possible mechanistic basis for the ability of CRL4 to
support an S phase checkpoint in response to crosslink-
ing agents is provided by the finding that ssDNA forma-
tion at ICLs is dependent on robust monoubiquitination
of the FA pathway member FANCD2. Once monoubi-
quitinated, this factor is known to recruit nucleases in-
cluding XPF-ERCC1 to ICL sites [8, 37–40, 52]. We
observed that CRL4 activity supports the monoubiquiti-
nation of FANCD2 and that this enhanced modification
is needed for the nuclease recruitment to ICLs (Fig. 8).
XPF-ERCC1 is a structure-specific endonuclease that un-
hooks the ICLs without yielding large stretches of ssDNA.
However, subsequent DNA resection for example by the
MRE11-RAD50-NBS1 complex or by CtIP, which also
interact with FANCD2 [41, 53], may ultimately be respon-
sible for the observed ssDNA foci at ICLs. In any case, our
findings suggest that the fraction of monoubiquitinated
FANCD2 must exceed a critical threshold to trigger the
recruitment of XPF-ERCC1 to an extent that promotes
the display of ssDNA in response to ICLs. It is not clear
whether FANCD2 is a direct target of ubiquitination by
CRL4 or whether CUL4A/B depletion affects other mem-
bers of the FA pathway supporting the ubiquitination of
FANCD2. Nonetheless, our findings indicate that CRL4
activity is needed to overcome this critical threshold, such
that down regulation of CRL4 reduces the formation of
ssDNA at ICLs. The relevance of these findings is broad-
ened by the observation that CLR4 activity is needed for
the S phase checkpoint in response to both cisplatin and
MMC treatment, and that this role of CLR4 in ICL-
dependent checkpoint signaling extends to SKOV3 ovar-
ian carcinoma cells.
Conclusion
Taken together, at least a subset of cancer cells is vulner-
able to the combination of a crosslinking agent and CRL4
inhibition. One future challenge is to develop selective
CRL4 inhibitors to avoid side effects due to the unneces-
sary blockage of other cullin-type ubiquitin ligases. Also, it
is necessary to discover and validate biomarkers for the
identification of those cancer subsets that are most suscep-
tible to a combined treatment of crosslinking agents and
CRL4 inhibitors. Our study provides insight into a novel
function of CRL4 in mitigating the cytotoxicity of ICLs
through stimulation an FA pathway-dependent checkpoint
response. Consequently, CRL4 is a potential new thera-
peutic target to improve the anticancer efficacy of ICL-
inducing drugs.
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